Genome-scale screens identify factors regulating tumor cell responses to natural killer cells

Michal Sheffer1,2,3,4, Emily Lowry5, Nicky Beelen6,7

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Michal_Sheffer@dfci.havard.edu.

Nature Genetics
|July 13, 2021
PubMed

Insights

Human tumor cells sensitive to natural killer (NK) cells show mesenchymal traits and specific gene expression. These features may predict resistance to immune checkpoint inhibitors, guiding NK cell therapy development.

Area of Science:

  • Immunology
  • Cancer Biology
  • Genomics

Background:

  • Natural killer (NK) cells are crucial for innate immunity and cancer surveillance.
  • Understanding tumor cell factors influencing NK cell sensitivity is vital for immunotherapy development.

Purpose of the Study:

  • To systematically identify molecular features of human tumor cells that dictate their sensitivity to allogeneic NK cells.
  • To functionally interrogate genes regulating tumor cell response to NK cells using CRISPR screens.

Main Methods:

  • Quantified NK cell responsiveness of hundreds of DNA-barcoded solid tumor cell lines.
  • Performed genome-scale CRISPR-based gene-editing screens in solid tumor cell lines.
  • Analyzed transcriptional programs, gene expression (B7-H6, HLA-E), and chromatin remodeling signatures.

Main Results:

  • NK cell-sensitive tumor cells exhibit mesenchymal-like transcriptional programs.
  • High expression of chromatin remodeling complexes and B7-H6 (NCR3LG1) correlates with sensitivity.
  • Low expression of HLA-E and antigen presentation genes is associated with NK cell sensitivity.
  • Transcriptional signatures of sensitive cells correlate with resistance to immune checkpoint inhibitors (ICIs) in clinical samples.

Conclusions:

  • Identified key molecular determinants of tumor cell sensitivity to NK cells.
  • Provides a comprehensive map of mechanisms regulating tumor cell-NK cell interactions.
  • Findings have implications for developing biomarker-driven NK cell immunotherapies and predicting ICI resistance.